Atea Pharmaceuticals Inc

Stock Chart, Company Information, and Scan Results

$6.16(as of Mar 9, 3:59 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Atea Pharmaceuticals Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$6.16
Ticker SymbolAVIR
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees55
CountyUSA
Market Cap$460.2M

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Atea Pharmaceuticals Inc In Our Stock Scanner

As of Mar 09, 2026
As of ---
As of ---
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.